Survivin and YM155: How faithful is the liaison?

Altieri, 2013, Targeting survivin in cancer, Cancer Lett., 332, 225, 10.1016/j.canlet.2012.03.005 Sah, 2006, Structural, functional and therapeutic biology of survivin, Cancer Lett., 244, 164, 10.1016/j.canlet.2006.03.007 Altieri, 2010, Survivin and IAP proteins in cell-death mechanisms, Biochem. J., 430, 199, 10.1042/BJ20100814 Knauer, 2007, Survivin's dual role: an export's view, Cell Cycle, 6, 518, 10.4161/cc.6.5.3902 Castedo, 2004, Cell death by mitotic catastrophe: a molecular definition, Oncogene, 23, 2825, 10.1038/sj.onc.1207528 Wheatley, 2005, Survivin: a protein with dual roles in mitosis and apoptosis, Int. Rev. Cytol., 247, 35, 10.1016/S0074-7696(05)47002-3 Church, 2012, Survivin in solid tumors: rationale for development of inhibitors, Curr. Oncol. Rep., 14, 120, 10.1007/s11912-012-0215-2 Rödel, 2012, Survivin as a prognostic/predictive marker and molecular target in cancer therapy, Curr. Med. Chem., 19, 3679, 10.2174/092986712801661040 Lladser, 2011, Is survivin the potential Achilles' heel of cancer?, Adv. Cancer Res., 111, 1, 10.1016/B978-0-12-385524-4.00001-5 Ryan, 2009, Survivin: a new target for anti-cancer therapy, Cancer Treat. Rev., 35, 553, 10.1016/j.ctrv.2009.05.003 Caldas, 2005, Survivin splice variants regulate the balance between proliferation and cell death, Oncogene, 24, 1994, 10.1038/sj.onc.1208350 Knauer, 2007, The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein, Cell Cycle, 6, 1502, 10.4161/cc.6.12.4305 Span, 2006, Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?, Clin. Chem., 52, 1693, 10.1373/clinchem.2006.071613 Végran, 2011, Apoptosis gene signature of survivin and its splice variant expression in breast carcinoma, Endocr. Relat. Cancer, 18, 783, 10.1530/ERC-11-0105 Végran, 2007, Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer, Oncogene, 26, 290, 10.1038/sj.onc.1209784 O'Connor, 2000, Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin, Proc. Natl. Acad. Sci. U. S. A., 97, 13103, 10.1073/pnas.240390697 Barrett, 2009, Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity, Cell Cycle, 8, 278, 10.4161/cc.8.2.7587 Surova, 2013, Various modes of cell death induced by DNA damage, Oncogene, 32, 3789, 10.1038/onc.2012.556 Yamamoto, 2008, Cancer cells survive with survivin, Cancer Sci., 99, 1709, 10.1111/j.1349-7006.2008.00870.x Riolo, 2012, Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer, J. Biol. Chem., 287, 10885, 10.1074/jbc.M111.308791 Wang, 2010, Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity, J. Biol. Chem., 285, 36129, 10.1074/jbc.M110.152777 Arora, 2007, Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)–XAF1 complex, J. Biol. Chem., 282, 26202, 10.1074/jbc.M700776200 Cheung, 2008, The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways, Mol. Biol. Cell, 19, 2729, 10.1091/mbc.E08-01-0107 Gu, 2012, Surf the post-translational modification network of p53 regulation, Int. J. Biol. Sci., 8, 672, 10.7150/ijbs.4283 Schneider, 2011, NFkappaB/p53 crosstalk — a promising new therapeutic target, Biochim. Biophys. Acta, 1815, 90 Hoffman, 2002, Transcriptional repression of the anti-apoptotic survivin gene by wild type p53, J. Biol. Chem., 277, 3247, 10.1074/jbc.M106643200 Mirza, 2002, Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway, Oncogene, 21, 2613, 10.1038/sj.onc.1205353 Schneider, 2010, Cross talk between stimulated NF-kappaB and the tumor suppressor p53, Oncogene, 29, 2795, 10.1038/onc.2010.46 Brandl, 2012, Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress, J. Mol. Cell Biol., 4, 284, 10.1093/jmcb/mjs013 Frank, 2011, The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation, Mol. Cell. Biol., 31, 1201, 10.1128/MCB.01136-10 Wang, 2008, Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis, Mol. Cell, 32, 11, 10.1016/j.molcel.2008.09.011 Estève, 2005, Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters, Proc. Natl. Acad. Sci. U. S. A., 102, 1000, 10.1073/pnas.0407729102 Xu, 2007, Sp1 and Sp3 regulate basal transcription of the survivin gene, Biochem. Biophys. Res. Commun., 356, 286, 10.1016/j.bbrc.2007.02.140 Krämer, 2006, Acetylation of Stat1 modulates NF-kappaB activity, Genes Dev., 20, 473, 10.1101/gad.364306 Füllgrabe, 2011, Histone onco-modifications, Oncogene, 30, 3391, 10.1038/onc.2011.121 Yun, 2011, Readers of histone modifications, Cell Res., 21, 564, 10.1038/cr.2011.42 Estève, 2007, Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells, J. Biol. Chem., 282, 2615, 10.1074/jbc.M606203200 Smallwood, 2007, Functional cooperation between HP1 and DNMT1 mediates gene silencing, Genes Dev., 21, 1169, 10.1101/gad.1536807 Hervouet, 2010, Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme, Cell Death Dis., 1, e8, 10.1038/cddis.2009.7 Kanwar, 2013, Survivin signaling in clinical oncology: a multifaceted dragon, Med. Res. Rev., 33, 765, 10.1002/med.21264 Aggarwal, 2009, Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?, Ann. N. Y. Acad. Sci., 1171, 59, 10.1111/j.1749-6632.2009.04911.x Guo, 2012, Interleukin-6 signaling pathway in targeted therapy for cancer, Cancer Treat. Rev., 38, 904, 10.1016/j.ctrv.2012.04.007 Clevers, 2012, Wnt/beta-catenin signaling and disease, Cell, 149, 1192, 10.1016/j.cell.2012.05.012 Whitfield, 2009, Calcium, calcium-sensing receptor and colon cancer, Cancer Lett., 275, 9, 10.1016/j.canlet.2008.07.001 Obexer, 2009, Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis, Mol. Biol. Cell, 20, 2041, 10.1091/mbc.E08-07-0699 Hagenbuchner, 2013, BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery, Oncogene, 32, 4748, 10.1038/onc.2012.500 Hagenbuchner, 2013, Mitochondria and FOXO3: breath or die, Front. Physiol., 4, 147, 10.3389/fphys.2013.00147 Knauer, 2007, Nuclear export is essential for the tumor-promoting activity of survivin, FASEB J., 21, 207, 10.1096/fj.06-5741com Pal Bhadra, 2012, Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF-1 by altering chromatin of STAT response element in A375 cells, BMC Cancer, 12, 180, 10.1186/1471-2407-12-180 Spange, 2009, Acetylation of non-histone proteins modulates cellular signalling at multiple levels, Int. J. Biochem. Cell Biol., 41, 185, 10.1016/j.biocel.2008.08.027 Zhu, 2012, TSA-induced JMJD2B downregulation is associated with cyclin B1-dependent survivin degradation and apoptosis in LNCap cells, J. Cell. Biochem., 113, 2375, 10.1002/jcb.24109 Jin, 2012, SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin, Pathol. Oncol. Res., 18, 713, 10.1007/s12253-012-9499-7 Hsu, 2012, Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells, Biochim. Biophys. Acta, 1820, 104, 10.1016/j.bbagen.2011.11.011 Lachenmayer, 2012, Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib, J. Hepatol., 56, 1343, 10.1016/j.jhep.2012.01.009 Krämer, 2009, HDAC2: a critical factor in health and disease, Trends Pharmacol. Sci., 30, 647, 10.1016/j.tips.2009.09.007 Zhang, 2012, VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin, Mol. Cell. Biochem., 361, 39, 10.1007/s11010-011-1085-x Yi, 2010, SIRT1 and p53, effect on cancer, senescence and beyond, Biochim. Biophys. Acta, 1804, 1684, 10.1016/j.bbapap.2010.05.002 Wieczorek, 2012, Acetylation modulates the STAT signaling code, Cytokine Growth Factor Rev., 23, 293, 10.1016/j.cytogfr.2012.06.005 Okamoto, 2011, Chitosan–interferon-beta gene complex powder for inhalation treatment of lung metastasis in mice, J. Control. Release, 150, 187, 10.1016/j.jconrel.2010.12.006 Pollok, 2013, Interferon alpha-armed nanoparticles trigger rapid and sustained STAT1-dependent anti-viral cellular responses, Cell. Signal., 25, 989, 10.1016/j.cellsig.2013.01.012 Coothankandaswamy, 2013, The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function, Biochem. J., 450, 169, 10.1042/BJ20121248 Thangaraju, 2006, SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases, Cancer Res., 66, 11560, 10.1158/0008-5472.CAN-06-1950 Thangaraju, 2009, Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3, Biochem. J., 417, 379, 10.1042/BJ20081132 Koppenol, 2011, Otto Warburg's contributions to current concepts of cancer metabolism, Nat. Rev. Cancer, 11, 325, 10.1038/nrc3038 Icard, 2012, A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells, Biochim. Biophys. Acta, 1826, 423 Bradner, 2010, Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease, Proc. Natl. Acad. Sci. U. S. A., 107, 12617, 10.1073/pnas.1006774107 Sehested, 1999, Transport of butyrate across the isolated bovine rumen epithelium–interaction with sodium, chloride and bicarbonate, Comp. Biochem. Physiol. A Mol. Integr. Physiol., 123, 399, 10.1016/S1095-6433(99)00082-3 Krämer, 2003, The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2, EMBO J., 22, 3411, 10.1093/emboj/cdg315 Zhang, 2011, Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2, Genes Dev., 25, 2610, 10.1101/gad.170605.111 Li, 1999, Pleiotropic cell-division defects and apoptosis induced by interference with survivin function, Nat. Cell Biol., 1, 461, 10.1038/70242 Li, 1998, Control of apoptosis and mitotic spindle checkpoint by survivin, Nature, 396, 580, 10.1038/25141 Baker, 2012, CDK4: a key player in the cell cycle, development, and cancer, Genes Cancer, 3, 658, 10.1177/1947601913478972 Retzer-Lidl, 2007, Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin, Int. J. Cancer, 121, 66, 10.1002/ijc.22619 Raj, 2008, Survivin repression by p53, Rb and E2F2 in normal human melanocytes, Carcinogenesis, 29, 194, 10.1093/carcin/bgm219 Jiang, 2004, Aberrant regulation of survivin by the RB/E2F family of proteins, J. Biol. Chem., 279, 40511, 10.1074/jbc.M404496200 Suzuki, 2001, Tumor cell “dead or alive”: caspase and survivin regulate cell death, cell cycle and cell survival, Histol. Histopathol., 16, 583 Suzuki, 2000, Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation, Oncogene, 19, 3225, 10.1038/sj.onc.1203665 Ito, 2000, Survivin promotes cell proliferation in human hepatocellular carcinoma, Hepatology, 31, 1080, 10.1053/he.2000.6496 Warfel, 2013, p21WAF1 and tumourigenesis: 20years after, Curr. Opin. Oncol., 25, 52, 10.1097/CCO.0b013e32835b639e Fukuda, 2004, Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways, Blood, 103, 120, 10.1182/blood-2003-05-1756 Nakahara, 2007, YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts, Cancer Res., 67, 8014, 10.1158/0008-5472.CAN-07-1343 Yamauchi, 2012, Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression, Biochem. Biophys. Res. Commun., 425, 711, 10.1016/j.bbrc.2012.07.103 Nakamura, 2012, ILF3/NF110 is a target of YM155, a suppressant of survivin, Mol. Cell. Proteomics, 11, 10.1074/mcp.M111.013243 Cheng, 2012, Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter, Int. J. Biochem. Mol. Biol., 3, 179 Grinstein, 2002, Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells, Oncogene, 21, 1485, 10.1038/sj.onc.1205211 Tolcher, 2008, Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin, J. Clin. Oncol., 26, 5198, 10.1200/JCO.2008.17.2064 Iwai, 2009, Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-napht ho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant, Drug Metab. Dispos., 37, 1856, 10.1124/dmd.109.027359 Aoyama, 2012, Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment, Cancer Chemother. Pharmacol., 70, 373, 10.1007/s00280-012-1913-z Aoyama, 2013, Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma, Invest. New Drugs, 31, 443, 10.1007/s10637-012-9867-x Minematsu, 2009, Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-napht ho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells, Drug Metab. Dispos., 37, 619, 10.1124/dmd.108.025254 Minematsu, 2010, Drug Metab. Dispos., 38, 1, 10.1124/dmd.109.028142 Iwai, 2011, Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC–PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein, Drug Metab. Dispos., 39, 2314, 10.1124/dmd.111.040733 Lamers, 2012, Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression, Eur. J. Cancer, 48, 763, 10.1016/j.ejca.2011.10.012 Risbridger, 2010, Breast and prostate cancer: more similar than different, Nat. Rev. Cancer, 10, 205, 10.1038/nrc2795 Joshua, 2008, Prostatic preneoplasia and beyond, Biochim. Biophys. Acta, 1785, 156 Zumsteg, 2012, Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?, Lancet Oncol., 13, e259, 10.1016/S1470-2045(12)70084-0 van Bokhoven, 2001, Widely used prostate carcinoma cell lines share common origins, Prostate, 47, 36, 10.1002/pros.1045 Murakami, 2013, Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model, Nucl. Med. Biol., 40, 221, 10.1016/j.nucmedbio.2012.10.002 Wang, 2011, Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells, Cancer Lett., 302, 29, 10.1016/j.canlet.2010.12.007 Tyner, 2012, Targeting survivin and p53 in pediatric acute lymphoblastic leukemia, Leukemia, 26, 623, 10.1038/leu.2011.249 Baudis, 2006, ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A–HLF expression, Pediatr. Blood Cancer, 47, 757, 10.1002/pbc.20635 Okuya, 2010, Up-regulation of survivin by the E2A–HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells, J. Biol. Chem., 285, 1850, 10.1074/jbc.M109.023762 Bernasconi, 2013, Early gene expression changes by Epstein–Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases, Int. J. Cancer, 133, 2341, 10.1002/ijc.28239 Chang, 2004, Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression, Proc. Natl. Acad. Sci. U. S. A., 101, 13239, 10.1073/pnas.0405407101 Huang, 2006, Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid, Semin. Oncol., 33, 479, 10.1053/j.seminoncol.2006.04.010 Sun, 2011, Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma, J. Thorac. Oncol., 6, 8, 10.1097/JTO.0b013e3181fa646a Leung, 2007, Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells, J. Exp. Med., 204, 1603, 10.1084/jem.20062395 Gallo, 2011, Research and discovery of the first human cancer virus, HTLV-1, Best Pract. Res. Clin. Haematol., 24, 559, 10.1016/j.beha.2011.09.012 Chen, 2013, Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia, Blood, 121, 2029, 10.1182/blood-2012-05-427773 Mori, 2001, Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells, Biochem. Biophys. Res. Commun., 282, 1110, 10.1006/bbrc.2001.4708 Jiang, 2009, Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy, Br. J. Haematol., 145, 173, 10.1111/j.1365-2141.2009.07606.x Kawakami, 2005, Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax, Int. J. Cancer, 115, 967, 10.1002/ijc.20954 Banerjee, 2008, Human T-cell lymphotropic virus type 1 infection of CD34+ hematopoietic progenitor cells induces cell cycle arrest by modulation of p21(cip1/waf1) and survivin, Stem Cells, 26, 3047, 10.1634/stemcells.2008-0353 Jeong, 2004, HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity, Blood, 104, 1490, 10.1182/blood-2003-12-4174 Ng, 2011, Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling, J. Pathol., 223, 496, 10.1002/path.2823 Kita, 2011, Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma, Leuk. Res., 35, 787, 10.1016/j.leukres.2010.11.016 Kita, 2012, Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab, J. Pharmacol. Exp. Ther., 343, 178, 10.1124/jpet.112.195925 Gupta, 2012, Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy, Leukemia, 26, 1356, 10.1038/leu.2011.340 Kaneko, 2013, Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma, Leuk. Res., 37, 1156, 10.1016/j.leukres.2013.05.010 Caceres-Cortes, 2008, A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490, Anticancer Agents Med Chem., 8, 717, 10.2174/187152008785914752 Song, 2005, A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells, Proc. Natl. Acad. Sci. U. S. A., 102, 4700, 10.1073/pnas.0409894102 Krämer, 2009, A phosphorylation–acetylation switch regulates STAT1 signaling, Genes Dev., 23, 223, 10.1101/gad.479209 Marotta, 2011, Unraveling the complexity of basal-like breast cancer, Oncotarget, 2, 588, 10.18632/oncotarget.314 Crown, 2012, Emerging targeted therapies in triple-negative breast cancer, Ann. Oncol., 23, vi56, 10.1093/annonc/mds196 Song, 2013, Prognostic value of survivin expression in breast cancer patients: a meta-analysis, Tumour Biol., 34, 2053, 10.1007/s13277-013-0848-2 Yamanaka, 2011, YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer, Int. J. Oncol., 39, 569 Nakahara, 2011, Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models, Cancer Sci., 102, 614, 10.1111/j.1349-7006.2010.01834.x Polyak, 2002, Breast cancer gene discovery, Expert Rev. Mol. Med., 4, 1, 10.1017/S146239940200491X Dallaglio, 2012, Survivin: a dual player in healthy and diseased skin, J. Invest. Dermatol., 132, 18, 10.1038/jid.2011.279 McKenzie, 2012, Role of the apoptotic and mitotic regulator survivin in melanoma, Anticancer Res, 32, 397 Yamanaka, 2011, Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models, Clin. Cancer Res., 17, 5423, 10.1158/1078-0432.CCR-10-3410 Erovic, 2013, Merkel cell carcinoma: the past, the present, and the future, J. Skin Cancer, 2013, 929364, 10.1155/2013/929364 Miller, 2013, Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma, Curr. Treat. Options Oncol., 14, 249, 10.1007/s11864-013-0225-9 Arora, 2012, Survivin is a therapeutic target in merkel cell carcinoma, Sci. Transl. Med., 4, 133ra156, 10.1126/scitranslmed.3003713 Schrama, 2013, Survivin downregulation is not required for T antigen knockdown mediated cell growth inhibition in MCV infected merkel cell carcinoma cells, Int. J. Cancer, 132, 2980, 10.1002/ijc.27962 Lamers, 2011, Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe, Endocr. Relat. Cancer, 18, 657, 10.1530/ERC-11-0207 Lima, 2012, Glioblastoma: therapeutic challenges, what lies ahead, Biochim. Biophys. Acta, 1826, 338 Lai, 2012, Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity, Pediatr. Neonatol., 53, 199, 10.1016/j.pedneo.2012.04.008 Lanvin, 2013, Radiation-induced mitotic cell death and glioblastoma radioresistance: A new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1alpha and survivin in U87 cells, Eur. J. Cancer, 49, 2884, 10.1016/j.ejca.2013.05.003 Anderson, 2000, Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8, Radiat. Res., 154, 473, 10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2 Virsik-Köpp, 2003, Role of DNA-PK in the process of aberration formation as studied in irradiated human glioblastoma cell lines M059K and M059J, Int. J. Radiat. Biol., 79, 61, 10.1080/713864982 Christmann, 2013, Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation, Nucleic Acids Res., 41, 8403, 10.1093/nar/gkt635 Collis, 2005, The life and death of DNA-PK, Oncogene, 24, 949, 10.1038/sj.onc.1208332 Lin, 2012, DNA-dependent protein kinase regulated glioblastoma survival in doxorubicin-induced cytotoxicity, Genomic Med. Biomark. Health Sci., 4, 54, 10.1016/j.gmbhs.2012.04.007 Kumar, 2012, YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels, Mol. Cancer Ther., 11, 1988, 10.1158/1535-7163.MCT-12-0167 Poh, 2012, Effects of IL-6, IL-10 and TGF-beta on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells, Exp. Oncol., 34, 85 Guo, 2012, Epstein–Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma, Int. J. Mol. Med., 29, 574, 10.3892/ijmm.2012.889 Bauman, 2013, ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial, Br. J. Cancer, 109, 2096, 10.1038/bjc.2013.576 Katz, 2009, Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways, Expert Rev. Mol. Med., 11, e30, 10.1017/S1462399409001227 Lee, 2012, Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells, Int. J. Mol. Med., 30, 443, 10.3892/ijmm.2012.1013 Ghadimi, 2012, Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors, Clin. Cancer Res., 18, 2545, 10.1158/1078-0432.CCR-11-2592 Hingorani, 2013, BIRC5 expression is a poor prognostic marker in Ewing sarcoma, Pediatr. Blood Cancer, 60, 35, 10.1002/pbc.24290 Potratz, 2012, Ewing sarcoma: clinical state-of-the-art, Pediatr. Hematol. Oncol., 29, 1, 10.3109/08880018.2011.622034 Karosas, 2010, Ewing's sarcoma, Am. J. Health Syst. Pharm., 67, 1599, 10.2146/ajhp090526 Sonnemann, 2011, Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells, Eur. J. Cancer, 47, 1432, 10.1016/j.ejca.2011.01.015 Cao, 2013, Current status in chemotherapy for advanced pancreatic adenocarcinoma, Anticancer Res, 33, 1785 Yoon, 2012, The survivin suppressant YM155 potentiates chemosensitivity to Gemcitabine in the human pancreatic cancer cell line MiaPaCa-2, Anticancer Res, 32, 1681 Ye, 2007, Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma, World J. Gastroenterol., 13, 6264, 10.3748/wjg.13.6264 Charette, 2013, Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms, Cell Death Dis., 4, e471, 10.1038/cddis.2012.200 Zhao, 2011, Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells, PLoS One, 6, e21980, 10.1371/journal.pone.0021980 Min, 2012, Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin, Nat. Cell Biol., 14, 1203, 10.1038/ncb2590 Hartkamp, 2010, HtrA2, taming the oncogenic activities of WT1, Cell Cycle, 9, 2508, 10.4161/cc.9.13.12060 Tao, 2012, Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells, BMC Cancer, 12, 619, 10.1186/1471-2407-12-619 Akhtar, 2006, Survivin: role in diagnosis, prognosis, and treatment of bladder cancer, Adv Anat Pathol, 13, 122, 10.1097/00125480-200605000-00003 Custodio, 2012, Targeted therapies for advanced non-small-cell lung cancer: current status and future implications, Cancer Treat. Rev., 38, 36, 10.1016/j.ctrv.2011.04.001 Travis, 2004, Pathology and genetics tumors of the lung, pleura, thymus and heart, 341 Langer, 2013, Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC), Cancer Treat. Rev., 39, 252, 10.1016/j.ctrv.2012.05.003 Petersen, 2011, The morphological and molecular diagnosis of lung cancer, Dtsch. Arztebl. Int., 108, 525 Gompelmann, 2011, Advanced malignant lung disease: what the specialist can offer, Respiration, 82, 111, 10.1159/000329703 Iwasa, 2008, Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines, Clin. Cancer Res., 14, 6496, 10.1158/1078-0432.CCR-08-0468 Iwasa, 2010, Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs, Br. J. Cancer, 103, 36, 10.1038/sj.bjc.6605713 Nakahara, 2011, YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model, Anticancer Drugs, 22, 454, 10.1097/CAD.0b013e328344ac68 Sun, 2007, Lung cancer in never smokers — a different disease, Nat. Rev. Cancer, 7, 778, 10.1038/nrc2190 Gazdar, 2009, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, 28, S24, 10.1038/onc.2009.198 Tartarone, 2013, Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib, Lung Cancer, 81, 328, 10.1016/j.lungcan.2013.05.020 Okamoto, 2012, Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin, Mol. Cancer Ther., 11, 204, 10.1158/1535-7163.MCT-11-0638 Okamoto, 2010, Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations, Cancer Res., 70, 10402, 10.1158/0008-5472.CAN-10-2438 Roskoski, 2013, The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders, Expert Opin. Drug Discov., 8, 1165, 10.1517/17460441.2013.813015 Lee, 2012, The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53, Oncogene, 31, 3265, 10.1038/onc.2011.504 Haruki, 2005, Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro, J. Med. Genet., 42, 558, 10.1136/jmg.2004.029686 Reynoird, 2010, Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains, EMBO J., 29, 2943, 10.1038/emboj.2010.176 C.G.A.R. Network, 2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038/nature11404 Peifer, 2012, Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer, Nat. Genet., 44, 1104, 10.1038/ng.2396 Blum, 2009, The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells, Nat. Biotechnol., 27, 281, 10.1038/nbt.1527 Lee, 2013, Inhibition of pluripotent stem cell-derived teratoma formation by small molecules, Proc. Natl. Acad. Sci. U. S. A., 110, E3281, 10.1073/pnas.1303669110 Shan, 2009, Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway, Cancer Invest., 27, 604, 10.1080/07357900802337191 Kuo, 2004, Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells, J. Biol. Chem., 279, 55875, 10.1074/jbc.M407985200 Polyak, 2006, Roots and stems: stem cells in cancer, Nat. Med., 12, 296, 10.1038/nm1379 Erba, 2013, Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML), Invest. New Drugs, 31, 1023, 10.1007/s10637-013-9935-x Miura, 2011, Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer, Surg. Today, 41, 175, 10.1007/s00595-010-4390-1 Kanwar, 2010, Recent advances in anti-survivin treatments for cancer, Curr. Med. Chem., 17, 1509, 10.2174/092986710790979935 Tracey, 2005, Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively, J. Pathol., 206, 123, 10.1002/path.1768 Cheson, 2012, A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma, Cancer, 118, 3128, 10.1002/cncr.26510 Satoh, 2009, Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors, Clin. Cancer Res., 15, 3872, 10.1158/1078-0432.CCR-08-1946 Giaccone, 2009, Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer, J. Clin. Oncol., 27, 4481, 10.1200/JCO.2008.21.1862 Kelly, 2013, A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer, Ann. Oncol., 24, 2601, 10.1093/annonc/mdt249 Lewis, 2011, A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma, Invest. New Drugs, 29, 161, 10.1007/s10637-009-9333-6 Tolcher, 2012, A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer, Ann. Oncol., 23, 968, 10.1093/annonc/mdr353 Balk, 2003, Biology of prostate-specific antigen, J. Clin. Oncol., 21, 383, 10.1200/JCO.2003.02.083 Tang, 2011, Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263, Biochem. Pharmacol., 82, 1066, 10.1016/j.bcp.2011.07.064 Feng, 2013, YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells, Biochem. Biophys. Res. Commun., 435, 52, 10.1016/j.bbrc.2013.04.036 Na, 2012, YM155 induces EGFR suppression in pancreatic cancer cells, PLoS One, 7, e38625, 10.1371/journal.pone.0038625 Song, 2003, Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis, J. Biol. Chem., 278, 23130, 10.1074/jbc.M300957200 Krämer, 2008, Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis, Oncogene, 27, 732, 10.1038/sj.onc.1210677 Salehi, 2008, Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update, Endocr. Relat. Cancer, 15, 721, 10.1677/ERC-08-0012 Chao, 2006, The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells, Mol. Pharmacol., 69, 154, 10.1124/mol.105.015503 Glaros, 2012, The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response, Cancer Chemother. Pharmacol., 70, 207, 10.1007/s00280-012-1868-0 Shoemaker, 2006, The NCI60 human tumour cell line anticancer drug screen, Nat. Rev. Cancer, 6, 813, 10.1038/nrc1951 Roos, 2013, DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis, Cancer Lett., 332, 237, 10.1016/j.canlet.2012.01.007 Cann, 2011, Heterochromatin and the DNA damage response: the need to relax, Biochem. Cell Biol., 89, 45, 10.1139/O10-113 Capalbo, 2007, The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target, Strahlenther. Onkol., 183, 593, 10.1007/s00066-007-1800-4 Capalbo, 2010, Radiation-induced survivin nuclear accumulation is linked to DNA damage repair, Int. J. Radiat. Oncol. Biol. Phys., 77, 226, 10.1016/j.ijrobp.2009.12.001 Holmes, 2012, Cancer drug's survivin suppression called into question, Nat. Med., 18, 842, 10.1038/nm0612-842b Reichert, 2011, Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma, Radiother. Oncol., 101, 51, 10.1016/j.radonc.2011.06.037 Ling, 2012, A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity, PLoS One, 7, e45571, 10.1371/journal.pone.0045571 Brown, 2013, Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study, Pediatr. Blood Cancer, 60, 842, 10.1002/pbc.24404 Qin, 2007, Regulation of apoptosis and differentiation by p53 in human embryonic stem cells, J. Biol. Chem., 282, 5842, 10.1074/jbc.M610464200 Smith, 2012, Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk, Stem Cells Transl. Med., 1, 709, 10.5966/sctm.2012-0066 Yao, 2005, Nuclear proteins: promising targets for cancer drugs, Curr. Cancer Drug Targets, 5, 595, 10.2174/156800905774932815 Yagata, 2011, Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy, Breast Cancer, 18, 165, 10.1007/s12282-011-0254-9 Mok, 2011, Personalized medicine in lung cancer: what we need to know, Nat. Rev. Clin. Oncol., 8, 661, 10.1038/nrclinonc.2011.126 Arteaga, 2012, Treatment of HER2-positive breast cancer: current status and future perspectives, Nat. Rev. Clin. Oncol., 9, 16, 10.1038/nrclinonc.2011.177 Hansen, 2008, SPC3042: a proapoptotic survivin inhibitor, Mol. Cancer Ther., 7, 2736, 10.1158/1535-7163.MCT-08-0161